Latest Insider Transactions at Johnson & Johnson (JNJ)
This section provides a real-time view of insider transactions for Johnson & Johnson (JNJ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of JOHNSON & JOHNSON to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of JOHNSON & JOHNSON's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2022
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
248
-1.58%
|
$40,920
$165.89 P/Share
|
|
Feb 15
2022
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
903
+5.43%
|
-
|
|
Feb 14
2022
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,857
-2.47%
|
$978,119
$167.37 P/Share
|
|
Feb 14
2022
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,190
+5.22%
|
-
|
|
Feb 14
2022
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
1,190
-1.0%
|
$199,920
$168.85 P/Share
|
|
Feb 14
2022
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
3,297
+2.71%
|
-
|
|
Feb 14
2022
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-1.74%
|
$44,184
$168.85 P/Share
|
|
Feb 14
2022
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
866
+5.43%
|
-
|
|
Feb 14
2022
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
792
-2.4%
|
$133,056
$168.85 P/Share
|
|
Feb 14
2022
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,885
+8.03%
|
-
|
|
Feb 14
2022
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,520
-3.51%
|
$255,360
$168.85 P/Share
|
|
Feb 14
2022
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
BUY
Exercise of conversion of derivative security
|
Direct |
3,759
+7.98%
|
-
|
|
Feb 14
2022
|
Michael H Ullmann Exec VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
871
-0.57%
|
$146,328
$168.85 P/Share
|
|
Feb 14
2022
|
Michael H Ullmann Exec VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,407
+1.55%
|
-
|
|
Feb 14
2022
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
902
-6.04%
|
$151,536
$168.85 P/Share
|
|
Feb 14
2022
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,451
+14.1%
|
-
|
|
Feb 14
2022
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
695
-1.05%
|
$116,760
$168.85 P/Share
|
|
Feb 14
2022
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,896
+2.78%
|
-
|
|
Feb 14
2022
|
Mathai Mammen EVP, Pharm, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,335
-5.85%
|
$392,280
$168.85 P/Share
|
|
Feb 14
2022
|
Mathai Mammen EVP, Pharm, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
7,418
+15.68%
|
-
|
|
Feb 14
2022
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
921
-3.5%
|
$154,728
$168.85 P/Share
|
|
Feb 14
2022
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,248
+10.99%
|
-
|
|
Feb 14
2022
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,133
-1.36%
|
$526,344
$168.85 P/Share
|
|
Feb 14
2022
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+3.26%
|
-
|
|
Feb 14
2022
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
2,356
-1.02%
|
$395,808
$168.85 P/Share
|
|
Feb 14
2022
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,424
+2.29%
|
-
|
|
Feb 14
2022
|
Alex Gorsky Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,833
-0.87%
|
$811,944
$168.85 P/Share
|
|
Feb 14
2022
|
Alex Gorsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,129
+1.96%
|
-
|
|
Jan 14
2022
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
54,378
-19.39%
|
$9,081,126
$167.84 P/Share
|
|
Jan 14
2022
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
84,423
+23.14%
|
$5,487,495
$65.37 P/Share
|
|
Jan 14
2022
|
Alex Gorsky Director |
SELL
Payment of exercise price or tax liability
|
Direct |
150,943
-21.7%
|
$25,207,481
$167.84 P/Share
|
|
Jan 14
2022
|
Alex Gorsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
231,951
+25.01%
|
$15,076,815
$65.37 P/Share
|
|
Dec 09
2021
|
Alex Gorsky Director |
SELL
Bona fide gift
|
Direct |
12,640
-1.34%
|
-
|
|
Dec 07
2021
|
Robert J Decker VP Corporate Controller |
SELL
Open market or private sale
|
Direct |
5,000
-26.02%
|
$815,000
$163.21 P/Share
|
|
Dec 07
2021
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.65%
|
$360,000
$72.54 P/Share
|
|
Jun 09
2021
|
Michael H Ullmann Exec VP, General Counsel |
SELL
Bona fide gift
|
Direct |
912
-0.3%
|
-
|
|
Feb 12
2021
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
13,438
-3.23%
|
$2,217,270
$165.55 P/Share
|
|
Feb 12
2021
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
33,021
+7.21%
|
-
|
|
Feb 12
2021
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,696
-2.53%
|
$939,840
$165.55 P/Share
|
|
Feb 12
2021
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,873
+5.33%
|
-
|
|
Feb 12
2021
|
Michael E Sneed EVP, Global Corp Aff & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,113
-2.4%
|
$513,645
$165.55 P/Share
|
|
Feb 12
2021
|
Michael E Sneed EVP, Global Corp Aff & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,211
+6.51%
|
-
|
|
Feb 12
2021
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
4,678
-6.82%
|
$771,870
$165.55 P/Share
|
|
Feb 12
2021
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
13,136
+15.45%
|
-
|
|
Feb 12
2021
|
Paulus Stoffels Vice Chair, Exec Committee |
SELL
Payment of exercise price or tax liability
|
Direct |
14,317
-2.48%
|
$2,362,305
$165.55 P/Share
|
|
Feb 12
2021
|
Paulus Stoffels Vice Chair, Exec Committee |
BUY
Exercise of conversion of derivative security
|
Direct |
35,062
+5.64%
|
-
|
|
Feb 12
2021
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
6,065
-2.52%
|
$1,000,725
$165.55 P/Share
|
|
Feb 12
2021
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
13,606
+5.26%
|
-
|
|
Feb 12
2021
|
Michael H Ullmann Exec VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,494
-2.07%
|
$1,071,510
$165.55 P/Share
|
|
Feb 12
2021
|
Michael H Ullmann Exec VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,444
+4.34%
|
-
|